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INTRODUCTION
Developmental and epileptic encephalopathies (DEE) are clinically and genetically heterogeneous severe neurodevelopmental disorders. These conditions often start in infancy or early childhood and are characterized by intractable seizures, frequent epileptiform activity on EEG, and developmental slowing or regression. 1 A genetic etiology can be identified in upwards of 30% of individuals with DEE, predominantly de novo variants in genes encoding neuronal ion channels or proteins involved in synaptic transmission. 2 Voltage-gated calcium channels mediate the influx of calcium in response to membrane depolarization in excitable cells. In presynaptic nerve terminals, this calcium influx triggers transmitter release for synaptic transmission. Several neurological and cardiac disorders are caused by pathogenic variants in and encodes the functionally critical α1E-subunit of the CaV2 family member CaV2.3, which is widely expressed throughout the central nervous system and conducts high voltage-activated, rapidly inactivating R-type calcium currents which are used to initiate rapid synaptic transmission. [13] [14] [15] CACNA1E plays a role in rodent models of acquired epilepsy, 16; 17 and a recent meta-analysis of whole exome sequencing data of nearly 7,000 individuals with neurodevelopmental disorders implicates CACNA1E as a possible candidate gene. 18 However, in contrast to the other α1-subunits, pathogenic variants in CACNA1E have not been established as disease-causing in humans. KL Here, we clinically and functionally characterize a disorder of neuronal calcium channel dysfunction, caused by de novo missense variants in CACNA1E. We report 30 individuals who present with a spectrum of severe early-onset neurodevelopmental disorders characterized by severe to profound global developmental delay, significant hypotonia, and developmental and epileptic encephalopathy.
SUBJECTS AND METHODS

Study participants
This study was approved by the local institutional review boards of the participating centers. Informed consent for participation in this study was provided by all parents or legal guardians of minors or individuals with intellectual disability. Individuals with likely pathogenic CACNA1E variants were ascertained between June 2015 and May 2018 via an international collaborative network of research and diagnostic sequencing laboratories. Some participants were identified via GeneMatcher. 19 Individual 16 was ascertained from the Epi4K study. 20 Individuals 23 and 26 were ascertained from the Deciphering Developmental Disorders Study. 21 Individual 31 was ascertained from the UK National Institute for Health Research (NIHR) Bioresource for Rare Diseases. 22 The remaining participants were referred from collaborating researchers, clinicians, and diagnostic laboratories. Detailed medical history information, including developmental and epilepsy history, morphologic details, and neurological findings, was provided for each participant. Where required, reverse phenotyping was performed. 23 Available brain imaging and EEG data were reviewed for all participants. Epilepsy syndromes and seizure types were classified according to the International League Against Epilepsy (ILAE) classification criteria. 24; 25 
Variant identification and interpretation
Whole exome sequencing Trio whole exome sequencing (WES) was performed on a diagnostic basis at GeneDx (Gaithersburg, MD, USA) for Individuals 1, 5, 6, 11, and 25 as previously described, 26 at Ambry Genetics (Aliso Viejo, CA, USA)
for Individuals 13, 14, 20, and 29 27 and at ARUP Laboratories (Salt Lake City, UT, USA) for Individual 15 (Supplemental Methods). Research-based trio WES was performed for Individuals 3, 4, 7-9, 16-19, 21-23, 26-28, 33 . Individual 30 underwent WES as a mother-proband duo. Trio WES was performed as described previously for Individual 16 as part of the Epi4K project. 20 Individuals 23 and 26 were ascertained by reanalysis of the data from the Deciphering Developmental Disorders Study 28 as part of a local "Solving the Unsolved" project in Manchester (UK) and a Complementary Analysis Project #237. 21 Trio WES was performed for Individual 27 as described previously. 29 Sequencing methodology for the remaining participants is detailed in the Supplemental Methods. All candidate variants identified via WES were validated by Sanger sequencing, except for the recurrent c.1054G>A; p.(Gly352Arg) variant in Individual 8.
Whole genome sequencing
Research-based trio whole genome sequencing (WGS) was performed in Individuals 10, 24, and 31, as described in the Supplemental Methods. Candidate variants identified via WGS were validated by Sanger sequencing.
NGS panel analysis
Individual 12 underwent diagnostic NGS-based 1430 gene epilepsy panel testing (GeneDx, Gaithersburg, MD, USA). Individuals 2 and 32 underwent research epilepsy panel testing, as previously described. 30 The presence or absence of variants identified via epilepsy panel testing was confirmed via Sanger sequencing in participants and parents. Parental relationships were confirmed for Individuals 2 and 12 by short tandem repeat analysis. Parental DNA samples were unavailable for Individual 32.
Variant interpretation
All identified CACNA1E variants were interpreted according to the American College of Medical Genetics and Genomics standards and guidelines for the interpretation of sequence variants. 31 CACNA1E variants were considered likely pathogenic if they were confirmed to have occurred de novo in the affected individual with confirmed parental relationships and were not observed in a control cohort of 123,136 individuals in the Exome Aggregation Consortium (ExAC) 32 or genome Aggregation Database (gnomAD).
Functional analysis
Two laboratories independently investigated the effects of the domain II S6 and the domain II S4-S5 linker variants. Given the congruence of findings from these two groups, we combined the results into a single study. The two laboratories used different CaV2.3 channel backbones for mutagenesis, and slightly different experimental setups and approaches. In each case, appropriate wildtype controls were used, and no direct statistical comparisons between the two datasets were made. Prior studies characterizing the structure and function of CaV2.3 channels had examined the biophysical and electrophysiological properties of several variants that were artificially introduced into S6 segments of CaV2.3 channels, including p.Arg352Gly, p.Ile701Val/Gly, and p.Ala1720Gly. 33; 34 These prior findings were also compared with the results of our functional analyses.
Mutagenesis
The human CaV2.3-subunit (α1E-1, NCBI reference number: NM_001205293.1) in the pcDNA3. 
Transfection and expression in tsA201 cells
Human tsA201 cells, a transformed human kidney cell line stably expressing an SV40 temperaturesensitive T antigen (Sigma-Aldrich, Darmstadt, Germany), were cultured at 37°C, with 5% CO2 humidified atmosphere and grown in Dulbecco's modified Eagle medium + 10% (v/v) foetal bovine serum. For the domain II S6 mutants, transfections using "TransIT®-LT1" reagent (Mirus Bio LLC., Madison, WI, USA)
were performed for transient expression of wildtype or mutant α-subunits together with the β2dsubunit. We transfected 3.16 µg of total DNA in a molar ratio of 1:1. Only cells with green fluorescence were used for electrophysiological recordings. For the domain II S6 variants, we performed electrophysiological recordings of tsA201 cells that were transiently transfected with either wildtype or mutant α 1E -subunits together with the β 2d -subunit, confirmed by the green fluorescence of EGFP which was co-expressed via an internal ribosome entry site (IRES). For the domain II S4-S5 mutant and corresponding wildtype control, cells were transfected with CaV2.3 and rat β1b and α2δ subunits (3 µg each) along with eGFP, using the calcium phosphate method.
Electrophysiology
Standard whole-cell recordings were performed using an Axopatch 200B amplifier, a Digidata 1320A or Digidata 1440A digitizer and pCLAMP 8 or 10.2 data acquisition software (Molecular Devices, Sunnyvale, CA, USA). Leakage and capacitive currents were automatically subtracted using a pre-pulse protocol (-P/4) for the domain II S6 variants. Currents were filtered at 3 or 5 kHz and digitized at 10 kHz. All recordings were performed at room temperature of 21-23°C. The liquid junction potential was calculated to be at 10. MgCl2, 10 HEPES, 10 EGTA, 3 ATP, 0.5 GTP (pH:7.4 adjusted with CsOH). Borosilicate glass pipettes had a final tip resistance of 1-2 MΩ when filled with internal recording solution. We carefully checked that the maximal voltage error due to residual series resistance after up to 95% compensation was always <5 mV.
Voltage clamp protocols and data analysis
The membrane was depolarized to various test potentials from a holding potential of -90 mV to record Ba 2+ currents. The activation curve (conductance-voltage relationship) was derived from the currentvoltage relationship obtained by plotting the peak current against various step depolarizations according to:
( ) = − with g being the conductance, I the recorded peak current at test potential V, and Vrev the apparent observed Ba 2+ reversal potential. Although the I-V relationship was not free of gating disturbances, we determined the apparent reversal potential by fitting the current-voltage relationship between -70 mV and 20 mV.
The following Boltzmann function was fit to the conductance-voltage relationship:
with g being the conductance at test potential V, gmax the maximal conductance, V1/2 the voltage of halfmaximal activation and kV a slope factor.
The residual current r400 was determined by dividing the peak Ba 2+ current IPeak of each current trace by the mean residual current Ires during the last 10 ms of a 400 ms voltage pulse. Channels were not completely inactivated at this time point, so that this value served as a surrogate parameter of the time course of inactivation. For wildtype and domain II S4-S5 mutant channels coexpressed with β1b, inactivation kinetics were quantified using monoexponential fits. To assess the time course of activation, a first-order exponential function was fitted to the current trace using ClampFit, yielding the activation time constant τact.
Data and statistical analysis
For variants in the domain II S6 segment, traces were displayed off-line with pClamp 10.4 (Molecular Devices, Sunnyvale, CA, USA). Fits were performed using gnuplot 5.0 (Freeware, T. Williams 
RESULTS
Clinical characteristics
We identified 30 
Seizure response to topiramate
Although seizures were resistant to multiple anti-epileptic drugs (AEDs) in most individuals for whom data were available (20/25; 80%), five individuals (1, 15, 16, 21, 27) reported significant improvement in seizure control with topiramate, the only AED noted to have a substantial effect on seizure control in any participants (Table S1 ). Two individuals (16 and 27) remain seizure-free for two and five years, respectively. However, in Individuals 15 and 21, seizures eventually recurred after seizure-free periods of four years and 18 months, respectively; Individual 21 died following an episode of status epilepticus.
Individual 1 reported a substantial reduction in seizure frequency with topiramate, but it was discontinued due to increased sedation. Topiramate had no effect on seizure control in 10/18 (56%) individuals who were prescribed it; 3/18 (17%) individuals who were prescribed topiramate reported a reduction in seizures but were never seizure-free. (Figure 1 ), which are presumed to form a crucial part of the activation gate in voltage-activated cation channels. 33; 34; 36 
Genetic analysis
Missense variants
Loss-of-function variants
In addition to the 30 individuals with missense variants, we identified three further individuals with CACNA1E variants that introduce premature termination codons predicted to result in haploinsufficiency, with no other known causative genetic variants identified (Individuals 31-33; 
Genotype-phenotype correlations
Functional analysis
Domain II S6 variants
We evaluated the functional effects of three missense variants (p.Phe698Ser, p.Ile701Val, and p.Ala702Thr) located in the cytoplasmic end of the S6 segment of domain II (IIS6; Figure 1 ). For the IIS6 variants, we performed electrophysiological recordings of tsA201 cells that were transiently transfected with either wildtype or mutant α1E-subunits together with the β2d-subunit, confirmed by the green fluorescence of EGFP which was co-expressed via an internal ribosome entry site (IRES). All three IIS6 variants exhibited consistent abnormalities of activation and inactivation kinetics compared to wildtype channels ( Figure 2 ; Table 2 ). The activation curve was shifted by approximately -10 mV for all three variants (Figure 2 ), while the time course of activation was not altered. Additionally, the time course of fast inactivation was significantly slowed, as indicated by an increased residual current after a 400-ms depolarizing pulse normalized to the peak current (r400) ( Figure 2 ; Table 2 ; Figure S1 ).
Domain II S4-S5 linker variant
The p.Ile603Leu variant, located in the domain II S4-S5 linker (IIS4-S5; Figure 1 ), was co-expressed with β1b and α2δ1 subunits in tsA201 cells and compared functionally to the wildtype channel. This variant resulted in a massive increase in whole cell current density (Figure 3 ; Figure S2 ) to a level that in many cases precluded functional biophysical characterization. In a subset of cells where the current could be properly clamped, our analysis revealed a >10 mV hyperpolarizing shift in half activation voltage ( Figure   3 ; Table 2 ; Figure S2 ). There was no significant effect on channel inactivation. containing six transmembrane segments (S1 to S6). The four S6 transmembrane helices line the channel pore, 36 and the structure at the cytoplasmic end of S6 segments contains the presumed activation gate and is crucial in channel gating. 33; 34 Disease-causing missense variants in our cohort clustered in cytoplasmic parts of all four S6 transmembrane segments, suggesting that the observed gain-of-function effects perturb the gating properties of the CaV2.3 channel.
DISCUSSION
Prior to our discovery of pathogenic variants in CACNA1E as a cause of human disease, selected variants had already been artificially introduced into different S6 segments in biophysical and electrophysiological studies to characterize the structure and function of CaV2.3 channels, and our functional analysis revealed results consistent with previous studies ( Figure S3 ). 33; 34 We now identify three previously-studied variants in CaV2. Although most disease-causing variants cluster in S6 transmembrane segments, the identified p.Ile603Leu variant is located in the linker between segments S4 and S5 in domain II. Functional analysis also identified strong gain-of-function properties for this variant, revealing increased current density and facilitated activation. These observed gain-of-function effects are also consistent with prior CaV2.3 biophysical studies showing that the domain II S4-S5 linker region is important for regulating channel activation. 40 In contrast to de novo missense variants with a gain-of-function effect, the role of CACNA1E haploinsufficiency is less clear. We identify three individuals with loss-of-function CACNA1E variants with comparably milder phenotypes. In one case the frameshift variant was transmitted from an unaffected parent. Several loss-of-function variants are reported in the gnomAD database, but loss-of-function variants do not appear to be well-tolerated in healthy individuals (pLI=1.0). 32 The AEDs topiramate and lamotrigine target CaV2.3 channels and reduce R-type calcium currents. 41; 42 Five individuals with CACNA1E-encephalopathy achieved seizure freedom on topiramate therapy, which was the only AED to meaningfully impact seizure control among any affected individuals. These data indicate that topiramate, an R-type channel blocker, has a positive effect in some individuals, possibly because its inhibitory mechanism targets the gain-of-function pathophysiology we have demonstrated in vitro. This is in stark contrast to a large number of other AEDs that did not show a sustained beneficial effect in more than a single individual.
In summary, we identified a genetic DEE associated with de novo missense variants in CACNA1E in 30 individuals, with notable features of congenital contractures and macrocephaly in many individuals.
Profound impairment with hypotonia and movement disorders were often part of the CACNA1E- facilitated R-type calcium currents as a disease mechanism in human epilepsy, which provides a promising target for the development of precision medicines for this devastating disease. Table S1 .
Table 2. Main electrophysiological parameters of IIS6 and IIS4-S5 variants causing a gain-of-function
V½ is the voltage of half-maximal activation, kV is a slope factor, r400 is the residual current in a 400-ms lasting pulse to 5 mV normalized to the peak current of the same trace, τinact is the exponential time constant of inactivation; numbers in brackets indicate the number of cells that were analysed for this parameter, data are represented as mean ± SEM; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 IIS6 variants in α1E-1 + β2d; 15mM Ba 2+ current density steady-state activation inactivation (pA/pF) V½ (mV) kV (mV) r400 at +5 mV
